References
- HylandK, ClaytonP. Aromatic amino acid decarboxylase deficiency in twins. J. Inherit. Metab. Dis.13(3), 301–304 (1990).
- HylandK, SurteesRA, RodeckC, ClaytonPT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology42(10), 1980–1988 (1992).
- WassenbergT, Molero-LuisM, JeltschKet al.Consensus guideline for the diagnosis and treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. Orphanet J. Rare Dis.12(1), 12 (2017).
- WilliamsK, SkrobanskiH, WernerC, O'neillS, BueschK, AcasterS. Symptoms and impact of aromatic L-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a patient-centred conceptual model. Curr. Med. Res. Opin.37(8), 1353–1361 (2021).
- HimmelreichN, MontioliR, BertoldiMet al.Aromatic amino acid decarboxylase deficiency: molecular and metabolic basis and therapeutic outlook. Mol. Genet. Metab.127(1), 12–22 (2019).
- BoiS, Garcia-MaloC, RodríguezCI. Oculogyric crisis: a rare type of dystonia. J. Psychiatry Neurosci.46(4), E429–e430 (2021).
- MahalP, SutharN, NebhinaniN. Spotlight on oculogyric crisis: a review. Indian J. Psychol. Med.43(1), 5–9 (2021).
- MoherD, LiberatiA, TetzlaffJ, AltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med.3(3), e123–130 (2009).
- FDA. Collection of race and ethnicity data in clinical trials (2016). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials
- ChenHC, ChenCL, KangLJ, WuCY, ChenFC, HongWH. Improvement of upper extremity motor control and function after home-based constraint induced therapy in children with unilateral cerebral palsy: immediate and long-term effects. Arch. Phys. Med. Rehabil.95(8), 1423–1432 (2014).
- ChenYP, KangLJ, ChuangTYet al.Use of virtual reality to improve upper-extremity control in children with cerebral palsy: a single-subject design. Phys. Ther.87(11), 1441–1457 (2007).
- DeKegel A, MaesL, Van WaelveldeH, DhoogeI. Examining the impact of Cochlear implantation on the early gross motor development of children with a hearing loss. Ear Hear.36(3), e113–121 (2015).
- XuK, WangL, MaiJ, HeL. Efficacy of constraint-induced movement therapy and electrical stimulation on hand function of children with hemiplegic cerebral palsy: a controlled clinical trial. Disabil. Rehabil.34(4), 337–346 (2012).
- TaiCH, LeeNC, ChienYHet al.Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol. Ther.30(2), 509–518 (2022).
- BrunL, NguLH, KengWTet al.Clinical and biochemical features of aromatic l-amino acid decarboxylase deficiency. Neurology75(1), 64–71 (2010).
- MallerA, HylandK, MilstienS, BiaggioniI, ButlerIJ. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J. Child Neurol.12(6), 349–354 (1997).
- Gene therapy for the treatment of AADC deficiency. https://ncats.nih.gov/trnd/projects/active/aadc-deficiency
- First therapy to treat rare genetic nervous system disorder AADC deficiency. https://www.ema.europa.eu/en/news/first-therapy-treat-rare-genetic-nervous-system-disorder-aadc-deficiency
- ChienYH, LeeNC, TsengSHet al.Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, Phase I/II trial. Lancet Child Adolesc. Health1(4), 265–273 (2017).
- HwuW-L, MuramatsuS-I, TsengS-Het al.Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med.4(134), 134ra161 (2012).
- KojimaK, NakajimaT, TagaNet al.Gene therapy improves motor and mental function of aromatic L-amino acid decarboxylase deficiency. Brain142(2), 322–333 (2019).
- KuseyriHübschmann O, HorvathG, Cortès-SaladelafontEet al.Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nat. Commun.12(1), 5529 (2021).